An unpublished observational study, presented at the European Respiratory Society Congress, indicates an association between the use of semaglutide and a lower hazard of airway exacerbations in individuals with diabetes. The research suggests a particularly strong association for people with asthma.
Dr Marie Spreckley, a researcher at the University of Cambridge, noted that the study identifies an association, but cannot establish a causal link. The reported hazard ratio of 0.20 suggests an estimated 80% lower hazard of airway exacerbations, though the confidence interval is wide.
Professor Stephen Burgess, also from the University of Cambridge, highlighted that as an observational study, it provides supportive evidence but not conclusive proof of an effect. He added that clinical trials are needed to validate any claims that semaglutide can reduce asthma attacks.
Dr Samantha Walker, Director of Research and Innovation at Asthma + Lung UK, described the study as promising. She stated that it indicates a significant reduction in asthma attacks and COPD flare-ups for people already taking semaglutide for conditions like diabetes.